Ayenew Berhan,Biruk Bayleyegn,Zegeye Getaneh
Ayenew Berhan
Lymphoma is one of the hematologic malignancies that occur at a higher rate in human immunodeficiency virus-infected individuals. It is one of the most frequent neoplastic causes of death in those individuals. Non-Hodgkin's lymphoma and Hod...
Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma [0.03%]
伊布替尼治疗新诊断老年原发中枢神经系统淋巴瘤患者的长期生存研究
Justin J Kuhlman,Muhamad Alhaj Moustafa,Liuyan Jiang et al.
Justin J Kuhlman et al.
Primary central nervous system lymphoma (PCNSL) carries a dismal prognosis in elderly patients above 70 years of age with a median overall survival of 6 months. Novel therapeutic agents are urgently needed to improve survival outcomes in th...
Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation [0.03%]
淋巴瘤相关脑葡萄糖低代谢的精神神经表现可通过强化葡萄糖补充逆转
Adam M Kase,Catherine Bullock,Ricardo Parrondo et al.
Adam M Kase et al.
Cerebral glucose hypometabolism (CGHM) is characterized by diffuse or focal reduction in uptake of glucose by the brain as determined on a FDG PET-CT. We report a case of lymphoma-associated cerebral glucose hypometabolism (LA-CGHM) in a pa...
How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice [0.03%]
我如何管理慢性髓系 leukemia(CML)患者——临床实践观点
Guru Subramanian Guru Murthy
Guru Subramanian Guru Murthy
The management of chronic myeloid leukemia (CML) has remarkably changed in the last 20 years with the availability of tyrosine kinase inhibitors (TKI). Most patients with chronic phase CML now have a life expectancy like that of age matched...
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia [0.03%]
急性淋巴细胞白血病中测量残留病灶的临床价值
Kyaw Hein,Nicholas Short,Elias Jabbour et al.
Kyaw Hein et al.
Measurable (minimal) residual disease (MRD) status in acute lymphoblastic leukemia (ALL) has largely superseded the importance of traditional risk factors for ALL, such as baseline white blood cell count, cytogenetics, and immunophenotype, ...
Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission [0.03%]
双重打击Richter转变的长期缓解的非移植成功治疗
Karan Seegobin,Muhamad Alhaj Moustafa,Liuyan Jiang et al.
Karan Seegobin et al.
Richter transformation (RT) is defined as the transformation of chronic lymphocytic leukemia (CLL) to a high-grade B cell lymphoma. It usually carries a dismal prognosis and represents an unmet need for novel therapeutic interventions. We r...
Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma [0.03%]
复发/难治滤泡性淋巴瘤患者的治疗新进展
Georgios Pongas,Bruce Cheson
Georgios Pongas
Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), ...
Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence [0.03%]
Ivosidenib治疗急性髓系白血病患者有效性和安全性的更新：现有证据综述
Galia Stemer,Jacob M Rowe,Yishai Ofran
Galia Stemer
The isocitrate dehydrogenase enzyme, catalyzing isocitrate conversion to α-ketoglutarate (αKG) in both the cell cytoplasm and mitochondria, contributes to the production of dihydronicotinamide-adenine dinucleotide phosphate (NADPH) as a r...
Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review [0.03%]
培甘司匹在儿童、青少年和年轻成人急性淋巴细胞白血病患者中的临床应用：综述
Cynthia Bender,Luke Maese,Maria Carter-Febres et al.
Cynthia Bender et al.
Acute lymphoblastic leukemia (ALL) is a heterogenous hematological malignancy representing 25% of all cancers in children less than 15 years of age. Significant improvements in survival and cure rates have been made over the past four decad...
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma [0.03%]
BCL2家族抑制剂在多发性骨髓瘤的生物学和治疗中的作用
Vikas A Gupta,James Ackley,Jonathan L Kaufman et al.
Vikas A Gupta et al.
Although much progress has been made in the treatment of multiple myeloma, the majority of patients fail to be cured and require numerous lines of therapy. Inhibitors of the BCL2 family represent an exciting new class of drugs with a novel ...